生物组织样本中拟甲状腺素索贝瑞罗浓度的定量分析。
Quantification of Thyromimetic Sobetirome Concentration in Biological Tissue Samples.
作者信息
Devereaux Jordan, Ferrara Skylar J, Scanlan Thomas S
机构信息
Program in Chemical Biology, Department of Physiology & Pharmacology, Oregon Health & Science University, Portland, OR, USA.
出版信息
Methods Mol Biol. 2018;1801:193-206. doi: 10.1007/978-1-4939-7902-8_16.
Abstract
Thyroid hormone is a principal regulator of essential processes in vertebrate physiology and homeostasis. Synthetic derivatives of thyroid hormone, known as thyromimetics, display desirable therapeutic properties. Thoroughly understanding how thyromimetics distribute throughout the body is crucial for their development and this requires appropriate bioanalytical techniques to quantify drug levels in different tissues. Here, we describe a detailed protocol for the quantification of the thyromimetic sobetirome using liquid chromatography tandem-mass spectrometry (LC-MS/MS).
摘要
甲状腺激素是脊椎动物生理学和体内平衡中基本过程的主要调节因子。甲状腺激素的合成衍生物，即甲状腺模拟物，具有理想的治疗特性。全面了解甲状腺模拟物在体内的分布情况对于其开发至关重要，而这需要合适的生物分析技术来量化不同组织中的药物水平。在此，我们描述了一种使用液相色谱串联质谱法（LC-MS/MS）定量甲状腺模拟物索比瑞林的详细方案。
相似文献
1
Quantification of Thyromimetic Sobetirome Concentration in Biological Tissue Samples.生物组织样本中拟甲状腺素索贝瑞罗浓度的定量分析。
Methods Mol Biol. 2018;1801:193-206. doi: 10.1007/978-1-4939-7902-8_16.
2
Sobetirome: a case history of bench-to-clinic drug discovery and development.索贝替欧：从实验室到临床的药物研发案例。
Heart Fail Rev. 2010 Mar;15(2):177-82. doi: 10.1007/s10741-008-9122-x. Epub 2008 Nov 11.
3
Targeting Fatty-Acid Amide Hydrolase with Prodrugs for CNS-Selective Therapy.用前药靶向脂肪酸酰胺水解酶进行中枢神经系统选择性治疗。
ACS Chem Neurosci. 2017 Nov 15;8(11):2468-2476. doi: 10.1021/acschemneuro.7b00239. Epub 2017 Aug 18.
4
Sobetirome prodrug esters with enhanced blood-brain barrier permeability.具有增强血脑屏障通透性的索贝替罗前药酯。
Bioorg Med Chem. 2016 Nov 15;24(22):5842-5854. doi: 10.1016/j.bmc.2016.09.038. Epub 2016 Sep 16.
5
Hypothalamic-Pituitary-Thyroid Axis Perturbations in Male Mice by CNS-Penetrating Thyromimetics.中枢神经系统穿透性甲状腺刺激剂致雄性小鼠下丘脑-垂体-甲状腺轴紊乱。
Endocrinology. 2018 Jul 1;159(7):2733-2740. doi: 10.1210/en.2018-00065.
6
Sobetirome: a selective thyromimetic for the treatment of dyslipidemia.索贝替罗姆：一种用于治疗血脂异常的选择性甲状腺模拟物。
Recent Pat Cardiovasc Drug Discov. 2011 Jan;6(1):16-9. doi: 10.2174/157489011794578473.
7
Sobetirome and its Amide Prodrug Sob-AM2 Exert Thyromimetic Actions in Mct8-Deficient Brain.索贝替欧及其酰胺前药 Sob-AM2 在 Mct8 缺陷的大脑中发挥甲状腺素激动作用。
Thyroid. 2018 Sep;28(9):1211-1220. doi: 10.1089/thy.2018.0008. Epub 2018 Jun 29.
8
Determination of thyroid hormones in mouse tissues by isotope-dilution microflow liquid chromatography-mass spectrometry method.采用同位素稀释微流液相色谱-质谱法测定小鼠组织中的甲状腺激素。
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 15;1033-1034:413-420. doi: 10.1016/j.jchromb.2016.08.037. Epub 2016 Aug 26.
9
Ester-to-amide rearrangement of ethanolamine-derived prodrugs of sobetirome with increased blood-brain barrier penetration.索贝替罗的乙醇胺衍生前药的酯到酰胺重排，其血脑屏障穿透性增强。
Bioorg Med Chem. 2017 May 15;25(10):2743-2753. doi: 10.1016/j.bmc.2017.03.047. Epub 2017 Mar 23.
10
Sobetirome: the past, present and questions about the future.索贝替欧：过去、现在与未来的问题。
Expert Opin Ther Targets. 2016;20(2):145-9. doi: 10.1517/14728222.2016.1090429. Epub 2015 Nov 13.
引用本文的文献
1
Effect of Thyromimetic GC-1 Selective Signaling on Reproductive and Lactational Performance in the Hypothyroid Rat.拟甲状腺素GC-1选择性信号传导对甲状腺功能减退大鼠生殖和泌乳性能的影响。
Eur Thyroid J. 2021 Jul;10(5):425-433. doi: 10.1159/000516432. Epub 2021 May 27.
2
Pharmacological Complementation Remedies an Inborn Error of Lipid Metabolism.药理补充疗法纠正脂质代谢先天性缺陷。
Cell Chem Biol. 2020 May 21;27(5):551-559.e4. doi: 10.1016/j.chembiol.2020.02.008. Epub 2020 Mar 12.
本文引用的文献
1
New synthetic routes to thyroid hormone analogs: d-sobetirome, H-sobetirome, and the antagonist NH-3.甲状腺激素类似物的新合成路线：d-索比美、H-索比美及拮抗剂NH-3。
Tetrahedron. 2015 Sep 2;71(35):5946-5951. doi: 10.1016/j.tet.2015.05.049. Epub 2015 May 20.
2
A Thyroid Hormone-Based Strategy for Correcting the Biochemical Abnormality in X-Linked Adrenoleukodystrophy.一种基于甲状腺激素的策略用于纠正X连锁肾上腺脑白质营养不良中的生化异常。
Endocrinology. 2017 May 1;158(5):1328-1338. doi: 10.1210/en.2016-1842.
3
Sobetirome prodrug esters with enhanced blood-brain barrier permeability.具有增强血脑屏障通透性的索贝替罗前药酯。
Bioorg Med Chem. 2016 Nov 15;24(22):5842-5854. doi: 10.1016/j.bmc.2016.09.038. Epub 2016 Sep 16.
4
Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver-selective thyroid hormone receptor agonist eprotirome.在接受肝选择性甲状腺激素受体激动剂 eprotirome 治疗的高胆固醇血症患者中，血清 LDL 胆固醇、载脂蛋白 B、甘油三酯和脂蛋白(a)水平降低。
J Intern Med. 2015 Mar;277(3):331-342. doi: 10.1111/joim.12261. Epub 2014 May 16.
5
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia.2-[3,5-二氯-4-(5-异丙基-6-氧代-1,6-二氢哒嗪-3-基氧基)苯基]-3,5-二氧代-2,3,4,5-四氢[1,2,4]三嗪-6-腈（MGL-3196）的发现，一种在治疗血脂异常的临床试验中具有高度选择性的甲状腺激素受体β激动剂。
J Med Chem. 2014 May 22;57(10):3912-23. doi: 10.1021/jm4019299. Epub 2014 Apr 8.
6
Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist.在健康志愿者中多次给予 MGL-3196（一种肝靶向甲状腺激素受体-β激动剂）治疗后的降脂作用。
Atherosclerosis. 2013 Oct;230(2):373-80. doi: 10.1016/j.atherosclerosis.2013.07.056. Epub 2013 Aug 21.
7
Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia.发现新型茚烷衍生物作为肝选择性甲状腺激素受体 β（TRβ）激动剂，用于治疗血脂异常。
Bioorg Med Chem. 2012 Jun 1;20(11):3622-34. doi: 10.1016/j.bmc.2012.03.056. Epub 2012 Apr 11.
8
Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia.使用甲状腺激素类似物 eprotirome 治疗他汀类药物治疗的血脂异常。
N Engl J Med. 2010 Mar 11;362(10):906-16. doi: 10.1056/NEJMoa0905633.
9
Sobetirome: a case history of bench-to-clinic drug discovery and development.索贝替欧：从实验室到临床的药物研发案例。
Heart Fail Rev. 2010 Mar;15(2):177-82. doi: 10.1007/s10741-008-9122-x. Epub 2008 Nov 11.
10
Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs.一系列肝脏选择性膦酸甲状腺激素受体激动剂及其前药的合成与生物学评价。
J Med Chem. 2008 Nov 27;51(22):7075-93. doi: 10.1021/jm800824d.
Zotero 插件